Potential mechanisms underlying anxiety and depression in Parkinson's disease: Consequences of l-DOPA treatment
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Though the most recognizable symptoms of Parkinson's disease (PD) are motor-related, many patients also suffer from debilitating affective symptoms that deleteriously influence quality of life. Dopamine (DA) loss is likely involved in the onset of depression and anxiety in PD. However, these symptoms are not reliably improved by DA replacement therapy with L-3,4-dihydroxyphenylalanine (L-DOPA). In fact, preclinical and clinical evidence suggests that L-DOPA treatment may worsen affect. Though the neurobiological mechanisms remain unclear, recent research contends that L-DOPA further perturbs the function of the norepinephrine and serotonin systems, already affected by PD pathology, which have been intimately linked to the development and expression of anxiety and depression. As such, this review provides an overview of the clinical characteristics of affective disorders in PD, examines the utility of animal models for the study of anxiety and depression in PD, and finally, discusses potential mechanisms by which DA loss and subsequent L-DOPA therapy influence monoamine function and concomitant affective symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stages in the development of Parkinson’s disease-related pathology
Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H., & Del Tredici, K. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0956-9 · Cited by 2,689 · cited 3×
“In support, the NE system is certainly affected by the disease process, as evidenced by the profound loss of noradrenergic neurons in the locus coeruleus that occurs prior to DA cell loss within the substantia nigra (Braak et al., 2004; Frisina et al., 2009).”
The role of dopamine in the pathophysiology of depression
Dunlop, B. W., & Nemeroff, C. B. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.3.327 · Cited by 1,244 · cited 1×
“Furthermore, DA has been linked to the development and treatment of affective disorders in the general population and in animal models of depression and anxiety (Chen & Skolnick, 2007; Dunlop & Nemeroff, 2007).”
Where Does Parkinson Disease Pathology Begin in the Brain?
Del Tredici, K., Rüb, U., de Vos, R. A. I., Bohl, J. R. E., & Braak, H. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.5.413 · Cited by 773
Chwastiak, L., Ehde, D. M., Gibbons, L. E., Sullivan, M., Bowen, J. D., & Kraft, G. H. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.11.1862 · Cited by 555 · cited 2×
“, 1999) or in other chronic and/or neurodegenerative diseases, such as multiple sclerosis (Chwastiak et al., 2002), Alzheimer's disease (Wragg & Jeste, 1989), and rheumatoid arthritis (Cantello et al.”
Quality of life in Parkinson's disease: the relative importance of the symptoms
Rahman, S., Griffin, H. J., Quinn, N. P., & Jahanshahi, M. (2008) · Movement Disorders · doi:10.1002/mds.21667 · Cited by 532
Medication-Related Impulse Control and Repetitive Behaviors in Parkinson Disease
Voon, V., & Fox, S. H. (2007) · Archives of Neurology · doi:10.1001/archneur.64.8.1089 · Cited by 397
Effect of Psychiatric and Other Nonmotor Symptoms on Disability in Parkinson's Disease
Weintraub, D., Moberg, P. J., Duda, J. E., Katz, I. R., & Stern, M. B. (2004) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2004.52219.x · Cited by 381
Prevalence of anxiety disorders and anxiety subtypes in patients with Parkinson's disease
Pontone, G. M., Williams, J. R., Anderson, K. E., Chase, G., Goldstein, S. A., Grill, S., Hirsch, E. S., Lehmann, S., Little, J. T., Margolis, R. L., et al. (2009) · Movement Disorders · doi:10.1002/mds.22611 · Cited by 305 · cited 3×
“Subtypes of anxiety due to a specific motor deficit (ie. fear of falling, agoraphobia) are substantially reduced upon onset of motor improvement due to L-DOPA treatment during the ON phase (Maricle et al., 1995, Pontone et al., 2009).”
Maricle, R. A., Nutt, J. G., Valentine, R. J., & Carter, J. H. (1995) · Neurology · doi:10.1212/wnl.45.9.1757 · Cited by 197
Menza, M., Dobkin, R. D., Marin, H., Mark, M. H., Gara, M., Buyske, S., Bienfait, K., & Dicke, A. (2009) · Movement Disorders · doi:10.1002/mds.22586 · Cited by 106 · cited 1×
“In fact, noradrenergic antidepressants, such as nortriptyline have recently proven to be more effective than selective 5-HT reuptake inhibitors in PD patients with depression (SSRIs; Menza et al., 2009), and may suggest a more prominent role for NE.”
Cited by
Depression in neurodegenerative diseases: Common mechanisms and current treatment options
Galts, C. P. C., Bettio, L. E. B., Jewett, D. C., Yang, C. C., Brocardo, P. S., Rodrigues, A. L. S., Thacker, J. S., & Gil-Mohapel, J. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.04.002 · Cited by 269
Biomarkers in Parkinson’s disease (recent update)
Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., Jelebinkov, M., Kurdi, Y., & Ebadi, M. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2013.06.005 · Cited by 242
“Early post-mortem data suggest that damage to brain serotonergic neurons might play a significant role in depression of PD (Karen et al., 2011).”
Levodopa in the Treatment of Parkinson's Disease: Current Status and New Developments
Salat, D., & Tolosa, E. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130186 · Cited by 232
“Additionally, the emergence of affective symptoms upon levodopa treatment initiation (and their remission with drug withdrawal) has been reported [80].”
BackgroundAnxiety in Parkinson’s disease: A critical review of experimental and clinical studies
Prediger, R. D. S., Matheus, F. C., Schwarzbold, M. L., Lima, M. M. S., & Vital, M. A. B. F. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.039 · Cited by 190
Dopamine dysregulation syndrome in Parkinson’s disease: a systematic review of published cases
Warren, N., O’Gorman, C., Lehn, A., & Siskind, D. (2017) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-315985 · Cited by 172
Parasites: evolution’s neurobiologists
Adamo, S. A. (2013) · Journal of Experimental Biology · doi:10.1242/jeb.073601 · Cited by 164
“Rodents treated with L-DOPA show an increase in anxiety (Eskow Jaunarajs et al., 2011).”
BackgroundSerotonin–dopamine interaction in the induction and maintenance of l-DOPA-induced dyskinesias
CARTA, M., CARLSSON, T., MUNOZ, A., KIRIK, D., & BJORKLUND, A. (2008) · Progress in brain research · doi:10.1016/s0079-6123(08)00922-9 · Cited by 131
Catecholamine/Serotonin Interactions
Hensler, J. G., Artigas, F., Bortolozzi, A., Daws, L. C., De Deurwaerdère, P., Milan, L., Navailles, S., & Koek, W. (2013) · Advances in Pharmacology · doi:10.1016/b978-0-12-411512-5.00009-9 · Cited by 73
“Based on the mechanism of action of L-DOPA, numerous strategies are available to control extracellular levels of DA produced by L-DOPA, opening therapeutic opportunities to improve L-DOPA therapy (Eskow et al., 2011; Navailles, Bioulac, et al., 2011).”
Background
Metadata
- Authors
- Eskow Jaunarajs, K. L., Angoa-Perez, M., Kuhn, D. M., & Bishop, C.
- Venue
- Neuroscience & Biobehavioral Reviews
- Publisher
- Elsevier BV
- Published
- 2011-01
- Volume
- 35
- Issue
- 3
- Pages
- 556-564
- ISSN
- 0149-7634 (ISSN-L)
- OpenAlex
- W1989123455
- Cited by
- 130
- References
- 13
- FWCI
- 4.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.